Domestic qutoju single anti-sea milestone: approved by the British NHS procurement, access to a number of top hospitals in Europe

Since Fuhong Hanxuan's independent development and production of Quto Zhudan anti-Hanquyou (HLX02, EU commodity name: Zercepac) in July-August this year in China and the European Union approved the simultaneous listing, its commercial progress in both China and Europe has been rapid progress, and achieved a series of bright results: Fuhong Hanxuan around "Don't let a HER2 positive patient fall" concept, and actively promote the commercialization of Hanquyou in China, the product was approved within 6 working days to facilitate a number of hospitals to issue the first prescription, successfully refreshed the industry record;
recently, Han Quyou also obtained a unified national medical insurance drug code, for the drug in China's clinical practice landing, better benefit more insured patients laid a foundation.
as a representative of the domestic biological medicine "going out to sea", the product has taken the lead in completing the commercialization of overseas markets "landing", has been listed in the United Kingdom, Germany, Portugal, Spain.
particularly noteworthy is the significant progress it has made in the UK in areas such as access to the NHS and public hospitals, which are considered to provide the best value for the NHS.
THE NHS fund is managed mainly by the NHS, with NHS England being the largest NHS in the UK, serving about 66m people, or more than 80 per cent of the UK population.
four areas under NHS England, where most public hospitals are generally tendered for medicines by the NHS system responsible for the region.
four regions, NHS London and surrounding areas manage a 15 billion pound (about $20 billion) health fund that serves more than 8 million people and is the largest public hospital procurement area in the UK, with about 10 per cent of all prescriptions in the region.
the EU was approved, HLX02, the EU's trade name: Zercepac, quickly won a bid to buy public hospitals in and around NHS London, meaning the product was recognised by NHS England.
the NHS's procurement principles for biologic drugs, HLX02, the EU trade name: Zercepac, is considered to offer the best value for the British public and NHS health care.
's bid to buy NHS London and surrounding areas also shows that HLX02 (HLX02, eu trade name: Zercepac) has entered or is about to enter the procurement area of a number of public hospitals, including a number of internationally renowned top general hospitals and cancer specialist hospitals, such as the Royal Marston Hospital, founded in 1851, is recognized as one of the world's best hospitals for breast cancer treatment, and the world's first dedicated to cancer diagnosis, treatment and teaching.
Marston Hospital, together with its academic partner, Cancer Research UK (ICR), forms the largest and most comprehensive cancer treatment centre in Europe.
in addition to the Royal Marsden Hospital, the region's leading hospitals include King's College Hospital in the UK (which has completed the conversion of medication for patients with clospoon monomaths), University Hospital of London, St George's Hospital, etc.
recognition of these world's top hospitals is another testament to the international quality and reputation of HLX02, the European Union's trade name: Zercepac.
the rapid commercialization of the European Union (HLX02, EU trade name: Zercepac) in the European Union, and continue to be recognized by european national health systems at the same time, Fu Hong Hanyu and Accord's cooperation is also expanding on this basis.
recently awarded Accord exclusive development and commercial rights to the product in the United States and Canada, making the commercial layout of the product fully cover the mainstream biopharmaceity market in Europe and the United States.
In the domestic high-quality biological medicine "sea" in Europe and the United States mainstream market journey, Fuhong Hanxuan took the lead in completing the milestone from external authorization to the commercialization of products, reached a new level, in the domestic market, Fuhong Hanxuan is also committed to improving product access, especially in the broad grass-roots market access, with the greatest efforts to practice the company "to high-quality biological drugs, the benefit of global patients" mission.
。